Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acute lymphoblastic leukemia

C H Pui1

  • 1Department of Hematology/Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

Pediatric Clinics of North America
|August 1, 1997
PubMed
Summary
This summary is machine-generated.

Molecular insights improve acute lymphoblastic leukemia (ALL) diagnosis and monitoring. Current research focuses on enhancing existing treatments and reducing side effects while awaiting targeted therapies for ALL subtypes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pre-B-Cell Acute Lymphoblastic Leukemia in Childhood.

Leukemia & lymphoma·2016
Same author

A revised definition for cure of childhood acute lymphoblastic leukemia.

Leukemia·2014
Same author

Successful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginase.

Cancer chemotherapy and pharmacology·2014
Same author

Calcium and cholecalciferol supplementation provides no added benefit to nutritional counseling to improve bone mineral density in survivors of childhood acute lymphoblastic leukemia (ALL).

Pediatric blood & cancer·2014
Same author

Results of treatment of advanced-stage lymphoblastic lymphoma at St Jude Children's Research Hospital from 1962 to 2002.

Annals of oncology : official journal of the European Society for Medical Oncology·2013
Same author

Cognitive outcomes following contemporary treatment without cranial irradiation for childhood acute lymphoblastic leukemia.

Journal of the National Cancer Institute·2012
Same journal

Barriers, Breakthroughs, and the Future of Pediatric Dermatologic Care.

Pediatric clinics of North America·2026
Same journal

Advancing Pediatric Dermatology: Innovations in Care and Access.

Pediatric clinics of North America·2026
Same journal

No Child Left Behind: Advancing Access in Pediatric Dermatology, a 4-Year, Single-Center Experience.

Pediatric clinics of North America·2026
Same journal

Telemedicine and Access to Pediatric Dermatology Care.

Pediatric clinics of North America·2026
Same journal

Inequitable Reimbursement for Pediatric Providers: A Review of Structural Factors that Disincentivize the Care of Children.

Pediatric clinics of North America·2026
Same journal

Medical Photography's Power to Change Medical Care.

Pediatric clinics of North America·2026
See all related articles

Area of Science:

  • Oncology
  • Hematology
  • Molecular Biology

Background:

  • Advances in molecular and immunologic characterization of leukemic cells have improved diagnosis and risk stratification for acute lymphoblastic leukemia (ALL).
  • Approximately 75% of childhood ALL cases exhibit genetically relevant abnormalities, underscoring the potential for molecularly targeted interventions.
  • Despite progress in understanding ALL genetics, direct translation into effective therapies remains a challenge.

Purpose of the Study:

  • To summarize current advancements in ALL diagnosis, risk assessment, and minimal residual disease monitoring.
  • To highlight strategies for optimizing existing ALL treatment regimens and mitigating toxicities.
  • To underscore the need for developing targeted therapies for genetically defined ALL subtypes.

Main Methods:

Related Experiment Videos

  • Review of recent findings in molecular and immunologic characterization of leukemic cells.
  • Analysis of clinical data on the efficacy and toxicity of modified treatment protocols.
  • Identification of key genetic abnormalities in childhood ALL.

Main Results:

  • High-dose methotrexate demonstrates improved efficacy, particularly in T-cell ALL.
  • Thiopurine S-methyltransferase (TPMT) deficiency can be identified prospectively, allowing for mercaptopurine dosage adjustments.
  • Dexrazoxane (ICRF-187) can mitigate anthracycline-induced cardiotoxicity.
  • Granulocyte colony-stimulating factor reduces hospital stays for febrile neutropenia.
  • Prolonged low-dose epipodophyllotoxin treatment may lower the risk of therapy-induced acute myeloid leukemia without compromising efficacy.

Conclusions:

  • Ongoing research aims to enhance current ALL treatment efficacy and reduce side effects.
  • Personalized treatment strategies based on genetic profiles are crucial for future ALL therapy.
  • The ultimate goal is to develop specific molecular interventions for genetically distinct ALL subtypes.